EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of Spinster homologue 2 (Spns2)‐dependent transport of sphingosine‐1‐phosphate as a therapeutic target

Yugesh Kharel, Tao Huang, Kyle Dunnavant, Daniel Foster, George M P R Souza, Katherine E Nimchuk, Andrea R Merchak, Caitlin M Pavelec, Zuzanna J Juskiewicz, Simon S Alexander, Alban Gaultier, Stephen B G Abbott und 6 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Yugesh Kharel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Lysophospholipids, Sphingosine, Anion Transport Proteins, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: US/DHHS/PHS/NIH, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Sphingosine‐1‐phosphate (S1P) receptor modulator (SRM) drugs suppress immune system function by disrupting lymphocyte trafficking, but SRMs are broadly immunosuppressive with on‐target liabilities. Another strategy to modulate the immune system is to block S1P transport. This study tests the hypothesis that blockers of S1P transport (STBs) mediated by Spinster homologue 2 (Spns2) approximate the efficacy of SRMs without their adverse events. Experimental Approach We have discovered and optimized STBs to enable investigations of S1P biology and to determine whether S1P transport is a valid drug target. The STB SLF80821178 was administered to rodents to assess its efficacy in a multiple sclerosis model and to test for toxicities associated with SRMs or Spns2‐deficient mice. Further, potential biomarkers of STBs, absolute lymphocyte counts (ALCs) in blood and S1P concentrations in plasma and lymph, were measured. Key Results SLF80821178 resembles SRMs in that it is efficacious in a standard multiple sclerosis model but does not evoke bradycardia or lung leakage, common to the SRM drug class. Also, chronic SLF80821178 administration does not affect auditory responses in adult mice despite the neurosensorial hearing defect observed in Spns2‐null mice. While both SRM and STB administration decrease ALCs, the maximal effect is less with an STB (45% vs. 90%). STBs have minimal effects on S1P concentration in plasma or thoracic duct lymph. Conclusion and Implications We found nothing to invalidate Spns2‐dependent S1P transport as a drug target. Indeed, STBs could be superior to SRMs as a therapy to modulate immune system function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysophospholipidsSphingosineAnion Transport ProteinsSphingosine 1 Phosphate Receptor ModulatorsAnimalsMiceMice, Inbred C57BLMaleEncephalomyelitis, Autoimmune, ExperimentalFemaleMultiple SclerosisBiological TransportMice, KnockoutHumansRatsImmunosuppressive Agents

Stichwörter der Autor:innen

S1P receptor modulatorsS1P transportS1P transport blockersSpns2sphingosine 1‐phosphate(S1P)

Substanzen

Lysophospholipidssphingosine 1-phosphateSphingosineAnion Transport ProteinsSpns2 protein, mouseSphingosine 1 Phosphate Receptor ModulatorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia, USA.
  • Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA.
  • Robert M. Berne Cardiovascular Research Center and Department of Molecular Physiology and Biophysics, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Microbiology, Immunology and Cancer Biology and Genetically Engineered Murine Model Core, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Kevin R Lynch

Förderung

  • US/DHHS/PHS/NIH
  • NIAID NIH HHS
  • NIH HHS
  • NIDCD NIH HHS
  • Virginia Commonwealth Commercialization Fund
  • NHLBI NIH HHS
  • NIA NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Kharel, Y., Huang, T., Dunnavant, K., Foster, D., Souza, G. M. P. R., Nimchuk, K. E., Merchak, A. R., Pavelec, C. M., Juskiewicz, Z. J., Alexander, S. S., Gaultier, A., Abbott, S. B. G., Shin, J. B., Isakson, B. E., Xu, W., Leitinger, N., Santos, W. L., & Lynch, K. R. (2025). Assessment of Spinster homologue 2 (Spns2)‐dependent transport of sphingosine‐1‐phosphate as a therapeutic target. British Journal of Pharmacology. https://doi.org/10.1111/bph.17456

Vancouver

Kharel Y, Huang T, Dunnavant K, Foster D, Souza GMPR, Nimchuk KE, et al. Assessment of Spinster homologue 2 (Spns2)‐dependent transport of sphingosine‐1‐phosphate as a therapeutic target. British Journal of Pharmacology. 2025. doi:10.1111/bph.17456

BibTeX
@article{Kharel2025,
  author = {Kharel, Yugesh and Huang, Tao and Dunnavant, Kyle and Foster, Daniel and Souza, George M P R and Nimchuk, Katherine E and Merchak, Andrea R and Pavelec, Caitlin M and Juskiewicz, Zuzanna J and Alexander, Simon S and Gaultier, Alban and Abbott, Stephen B G and Shin, Jung-Bum and Isakson, Brant E and Xu, Wehao and Leitinger, Norbert and Santos, Webster L and Lynch, Kevin R},
  title = {Assessment of Spinster homologue 2 (Spns2)‐dependent transport of sphingosine‐1‐phosphate as a therapeutic target},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17456}
}
Kostenlos starten →